Lung cancer, Colon cancer, Breast cancer
Conditions
Interventions
Paronosetoron 0.75mg d.i.v. 30 min prior to chemotherapy on Day1
Granisetoron 3mg d.i.v. 30 min prior to chemotherapy on Day1
Sponsors
Shimane University Faculty of Medicine Division of Clinical Oncology and Respiratory Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patient receiving HEC or MEC defined by Japan Society of Clinical Oncology guideline 2010, ver 1 2)ECOG performance status of 0-2 3)Acquisition of written informed consent
Exclusion criteria
Exclusion criteria: 1)Patient with dementia 2)Concurrent brain radiotherapy 3)Serious infections 4)Clinical brain metastasis 5)Massive pericardial, pleural effusion, or ascites 6)Vestibular disorder 7)Clinical hypercalcaemia or hyponatremia 8)Clinical uremia 9)Ireus or sub-ireus 10)Serious clinical probrems 11)Previous drug allergy 12)Hoped to be pregnant/ nursing 13)Those judged to be not suitable by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score of delayed CINV in MAT | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Score of nausea in FLIE 2)Score of vomiting in FLIE 3)Number of delayed vomiting 4)Number of acute vomiting 5)Number of acute nausea 6)Number of acute vomiting 7)Plasma concentration of 5-HIAA, Substance P and ghrelin | — |
Countries
Japan
Outcome results
None listed